RALLY TIME: Clearmind Medicine (CMND)

Dear Investor, I hope this email finds you well. I wanted to reach out to you to share an exciting opportunity that I recently came across in the biotech sector. The company is called CMND ([Clearmind Medicine]( and they are working on a groundbreaking new treatment for mental health disorders using psychedelic compounds. I came across an interesting article on the [Biotech Stock Periodical]( website that discusses the potential of this company and I think it's worth taking a closer look. [Read the full article here >>]( CMND is the first company to bring a psychedelic-based treatment for alcohol use disorder (AUD) to market, and the early results from their clinical trials are very promising. Since I last reached out to you, there have been a few notable developments with CMND that I wanted to bring to your attention. First, the company has received significant media coverage on MarketWatch, check out these headlines: - [Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND)]( - and here's one from last week: [Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)]( The articles highlight their progress in developing this treatment. In addition, the company recently announced that they have [secured the necessary funding and partnerships to begin clinical trials for this treatment]( which is a major milestone. In terms of the company's key statistics, it's important to note that CMND is still a relatively small company and there may be risks associated with investing in them. However, the potential reward could be significant if the treatment proves to be successful. According to the [Biotech Stock Periodical]( the market for AUD treatment is expected to reach $6.4 billion by 2027, and CMND's psychedelic-based treatment could capture a significant share of this market. Additionally, analysts have noted the company's strong patent portfolio and partnerships with major pharmaceutical companies as positive indicators for their future growth. CMND is a company to have on your radar TODAY, and I believe they have the potential to make a significant impact in the mental health industry. If you're interested in learning more, check out the full details on the [Biotech Stock Periodical website]( and consider consulting with a financial advisor or doing your own research before making any investment decisions. Best regards, Graham Fitzgerald Managing Editor, Tech Rallies P.S. Make sure you're getting all our CMND updates... [Sign up for FREE instant SMS alerts here >>]( Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. Tech Rallies full disclosure is to be read and fully understood before using Tech Rallies website, or joining Tech Rallies’ email or text list. By viewing Tech Rallies website and/or reading Tech Rallies' email or text newsletter you are agreeing toTech Rallies’s full disclosure which can be read at Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Tech Rallies (techrallies.com) are owned by Red Pill Media LLC, a limited liability company. Pursuant to an agreement between Red Pill Media LLC and TD Media LLC, Red Pill Media LLC has been hired for a period beginning on 1/3/2023 and ending on 1/4/2023 to publicly disseminate information about (CMND:US) via digital communications. We have been paid an additional eight thousand three hundred and thirty three dollars USD via bank wire transfer. To date we have been paid eight thousand three hundred and thirty three dollars USD via bank wire transfer to disseminate information about (CMND:US) via digital communications. We own zero shares of (CMND:US). Red Pill Media, LLC 3751 Far West Blvd, Austin TX 78733 3751 Far W Blvd Austin TX 78731 USA [Unsubscribe]( | [Change Subscriber Options](